Th1 cytokine-based immunotherapy for cancer

Hepatobiliary and Pancreatic Diseases International

Volumn 13, Issue 5, 2014, Pages 482-494

  Xu, Hong Mei ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

adjuvant therapy; cytokine; gene therapy

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; BCG VACCINE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL TRANSFER; HUMAN; IMMUNE RESPONSE; MYCOBACTERIUM BOVIS BCG; NONHUMAN; REVIEW; TH1 CELL; ANTAGONISTS AND INHIBITORS; CPG ISLAND; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; TUMOR MICROENVIRONMENT;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; CPG ISLANDS; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEAT-SHOCK PROTEINS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; INTERLEUKIN-1; INTERLEUKIN-12; INTERLEUKIN-2; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS; TUMOR MICROENVIRONMENT;

EID: 84936759299     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(14)60305-2     Document Type: Review

References (156)

1. JA Klapper, SG Downey, FO Smith, JC Yang, MS Hughes, US Kammula et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006 Cancer 113 2008 293 301
2. CA Dinarello Immunological and inflammatory functions of the interleukin-1 family Annu Rev Immunol 27 2009 519 550
3. J Schmitz, A Owyang, E Oldham, Y Song, E Murphy, TK McClanahan et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines Immunity 23 2005 479 490
4. SZ Ben-Sasson, J Hu-Li, J Quiel, S Cauchetaux, M Ratner, I Shapira et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation Proc Natl Acad Sci U S A 106 2009 7119 7124
5. + effector T cells J Immunol 176 2006 7278 7287
6. Z Guo, M Zhang, H An, W Chen, S Liu, J Guo et al. Fas ligation induces IL-1beta-dependent maturation and IL-1beta-independent survival of dendritic cells: different roles of ERK and NF-kappaB signaling pathways Blood 102 2003 4441 4447
7. Y Chung, SH Chang, GJ Martinez, XO Yang, R Nurieva, HS Kang et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling Immunity 30 2009 576 587
8. C Sutton, C Brereton, B Keogh, KH Mills, EC Lavelle A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis J Exp Med 203 2006 1685 1691
9. C Gabay, C Lamacchia, G Palmer IL-1 pathways in inflammation and human diseases Nat Rev Rheumatol 6 2010 232 241
10. Y Gu, K Kuida, H Tsutsui, G Ku, K Hsiao, MA Fleming et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme Science 275 1997 206 209
11. P Reddy Interleukin-18: recent advances Curr Opin Hematol 11 2004 405 410
12. MH Zaki, P Vogel, M Body-Malapel, M Lamkanfi, TD Kanneganti IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation J Immunol 185 2010 4912 4920
13. LA O'Neill The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress Immunol Rev 226 2008 10 18
14. K Takeda, H Tsutsui, T Yoshimoto, O Adachi, N Yoshida, T Kishimoto et al. Defective NK cell activity and Th1 response in IL-18-deficient mice Immunity 8 1998 383 390
15. + T cells to the tumor microenvironment Cancer Res 73 2013 4653 4662
16. ZL Jonak, S Trulli, C Maier, FL McCabe, R Kirkpatrick, K Johanson et al. High-dose recombinant interleukin-18 induces an effective Th1 immune response to murine MOPC-315 plasmacytoma J Immunother 25 2002 S20 S27
17. DW Ju, Y Yang, Q Tao, WG Song, L He, G Chen et al. Interleukin-18 gene transfer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity Gene Ther 7 2000 1672 1679
18. K Yoshimura, S Hazama, N Iizuka, S Yoshino, K Yamamoto, M Muraguchi et al. Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader sequence Cancer Gene Ther 8 2001 9 16
19. LH Zhang, JP Pan, HP Yao, WJ Sun, DJ Xia, QQ Wang et al. Intrasplenic transplantation of IL-18 gene-modified hepatocytes: an effective approach to reverse hepatic fibrosis in schistosomiasis through induction of dominant Th1 response Gene Ther 8 2001 1333 1342
20. DW Ju, Q Tao, G Lou, M Bai, L He, Y Yang et al. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates Cancer Res 61 2001 3735 3740
21. T Tatsumi, A Gambotto, PD Robbins, WJ Storkus Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy Cancer Res 62 2002 5853 5858
22. D Xia, S Zheng, W Zhang, L He, Q Wang, J Pan et al. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen J Mol Med (Berl) 81 2003 585 596
23. DJ Marshall, KA Rudnick, SG McCarthy, LR Mateo, MC Harris, C McCauley et al. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine Vaccine 24 2006 244 253
24. Q Wang, H Yu, DW Ju, L He, JP Pan, DJ Xia et al. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma Gene Ther 8 2001 542 550
25. S Dai, X Zhou, B Wang, Q Wang, Y Fu, T Chen et al. Enhanced induction of dendritic cell maturation and HLA-A∗0201-restricted CEA-specific CD8(+) CTL response by exosomes derived from IL-18 gene-modified CEA-positive tumor cells J Mol Med (Berl) 84 2006 1067 1076
26. D Robinson, K Shibuya, A Mui, F Zonin, E Murphy, T Sana et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB Immunity 7 1997 571 581
27. CM Coughlin, KE Salhany, M Wysocka, E Aruga, H Kurzawa, AE Chang et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis J Clin Invest 101 1998 1441 1452
28. T Tatsumi, J Huang, WE Gooding, A Gambotto, PD Robbins, NL Vujanovic et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity Cancer Res 63 2003 6378 6386
29. H Iinuma, K Okinaga, R Fukushima, T Inaba, K Iwasaki, A Okinaga et al. Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma J Immunol 176 2006 3461 3469
30. MC Rodriguez-Galan, D Reynolds, SG Correa, P Iribarren, M Watanabe, HA Young Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity J Immunol 183 2009 740 748
31. MJ Robertson, JW Mier, T Logan, M Atkins, H Koon, KM Koch et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer Clin Cancer Res 12 2006 4265 4273
32. AA Tarhini, M Millward, P Mainwaring, R Kefford, T Logan, A Pavlick et al. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma Cancer 115 2009 859 868
33. K Nakanishi, T Yoshimoto, H Tsutsui, H Okamura Interleukin-18 regulates both Th1 and Th2 responses Annu Rev Immunol 19 2001 423 474
34. F Vidal-Vanaclocha, L Mendoza, N Telleria, C Salado, M Valcárcel, N Gallot et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression Cancer Metastasis Rev 25 2006 417 434
35. MT Carrascal, L Mendoza, M Valcárcel, C Salado, E Egilegor, N Tellería et al. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium Cancer Res 63 2003 491 497
36. M Terme, E Ullrich, L Aymeric, K Meinhardt, M Desbois, N Delahaye et al. IL-18 induces PD-1-dependent immunosuppression in cancer Cancer Res 71 2011 5393 5399
37. M Terme, E Ullrich, L Aymeric, K Meinhardt, JD Coudert, M Desbois et al. Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells Cancer Res 72 2012 2757 2767
38. JC Markley, M Sadelain IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice Blood 115 2010 3508 3519
39. T Takeshita, H Asao, K Ohtani, N Ishii, S Kumaki, N Tanaka et al. Cloning of the gamma chain of the human IL-2 receptor Science 257 1992 379 382
40. JM Depper, WJ Leonard, C Drogula, M Krönke, TA Waldmann, WC Greene Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene Proc Natl Acad Sci U S A 82 1985 4230 4234
41. TR Malek, I Castro Interleukin-2 receptor signaling: at the interface between tolerance and immunity Immunity 33 2010 153 165
42. SC Wuest, JH Edwan, JF Martin, S Han, JS Perry, CM Cartagena et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy Nat Med 17 2011 604 609
43. AB Stittrich, C Haftmann, E Sgouroudis, AA Kühl, AN Hegazy, I Panse et al. The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes Nat Immunol 11 2010 1057 1062
44. S Feau, R Arens, S Togher, SP Schoenberger Autocrine IL-2 is required for secondary population expansion of CD8(+) memory T cells Nat Immunol 12 2011 908 913
45. W Liao, JX Lin, L Wang, P Li, WJ Leonard Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages Nat Immunol 12 2011 551 559
46. J Cote-Sierra, G Foucras, L Guo, L Chiodetti, HA Young, J Hu-Li et al. Interleukin 2 plays a central role in Th2 differentiation Proc Natl Acad Sci U S A 101 2004 3880 3885
47. + T regulatory cells J Immunol 178 2007 4022 4026
48. A Laurence, CM Tato, TS Davidson, Y Kanno, Z Chen, Z Yao et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation Immunity 26 2007 371 381
49. RJ Johnston, YS Choi, JA Diamond, JA Yang, S Crotty STAT5 is a potent negative regulator of TFH cell differentiation J Exp Med 209 2012 243 250
50. + regulatory T cells in cancer patients Blood 107 2006 2409 2414
51. JM Weiss, TC Back, AJ Scarzello, JJ Subleski, VL Hall, JK Stauffer et al. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment Proc Natl Acad Sci U S A 106 2009 19455 19460
52. J Dannull, Z Su, D Rizzieri, BK Yang, D Coleman, D Yancey et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells J Clin Invest 115 2005 3623 3633
53. AM Levin, DL Bates, AM Ring, C Krieg, JT Lin, L Su et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine" Nature 484 2012 529 533
54. F Ogawa, H Iinuma, K Okinaga Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells Scand J Immunol 59 2004 432 439
55. Y Yang, F Xiu, Z Cai, J Wang, Q Wang, Y Fu et al. Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells J Cancer Res Clin Oncol 133 2007 389 399
56. FO Smith, SG Downey, JA Klapper, JC Yang, RM Sherry, RE Royal et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines Clin Cancer Res 14 2008 5610 5618
57. DJ Schwartzentruber, DH Lawson, JM Richards, RM Conry, DM Miller, J Treisman et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma N Engl J Med 364 2011 2119 2127
58. SA Rosenberg Raising the bar: the curative potential of human cancer immunotherapy Sci Transl Med 4 2012 127ps8
59. G Trinchieri Interleukin-12 and the regulation of innate resistance and adaptive immunity Nat Rev Immunol 3 2003 133 146
60. B Oppmann, R Lesley, B Blom, JC Timans, Y Xu, B Hunte et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 Immunity 13 2000 715 725
61. + T cells Immunity 16 2002 779 790
62. JL Langowski, X Zhang, L Wu, JD Mattson, T Chen, K Smith et al. IL-23 promotes tumour incidence and growth Nature 442 2006 461 465
63. RA Kastelein, CA Hunter, DJ Cua Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation Annu Rev Immunol 25 2007 221 242
64. L Rogge, L Barberis-Maino, M Biffi, N Passini, DH Presky, U Gubler et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells J Exp Med 185 1997 825 831
65. MJ Brunda, L Luistro, RR Warrier, RB Wright, BR Hubbard, M Murphy et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors J Exp Med 178 1993 1223 1230
66. H Tahara, HJ Zeh 3rd, WJ Storkus, I Pappo, SC Watkins, U Gubler et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54 1994 182 189
67. S Adris, E Chuluyan, A Bravo, M Berenstein, S Klein, M Jasnis et al. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells Cancer Res 60 2000 6696 6703
68. Y Nishioka, M Hirao, PD Robbins, MT Lotze, H Tahara Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12 Cancer Res 59 1999 4035 4041
69. P Nanni, G Nicoletti, C De Giovanni, L Landuzzi, E Di Carlo, F Cavallo et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice J Exp Med 194 2001 1195 1205
70. N Okada, S Iiyama, Y Okada, H Mizuguchi, T Hayakawa, S Nakagawa et al. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12 Cancer Gene Ther 12 2005 72 83
71. T Suzuki, T Fukuhara, M Tanaka, A Nakamura, K Akiyama, T Sakakibara et al. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells Clin Cancer Res 11 2005 58 66
72. W Lasek, G Basak, T Switaj, AB Jakubowska, PJ Wysocki, A Mackiewicz et al. Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice Cancer Immunol Immunother 53 2004 363 372
73. MB Atkins, MJ Robertson, M Gordon, MT Lotze, M DeCoste, JS DuBois et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies Clin Cancer Res 3 1997 409 417
74. JP Leonard, ML Sherman, GL Fisher, LJ Buchanan, G Larsen, MB Atkins et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production Blood 90 1997 2541 2548
75. WK Kang, C Park, HL Yoon, WS Kim, SS Yoon, MH Lee et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study Hum Gene Ther 12 2001 671 684
76. G Mazzolini, C Alfaro, B Sangro, E Feijoó, J Ruiz, A Benito et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas J Clin Oncol 23 2005 999 1010
77. B Sangro, G Mazzolini, J Ruiz, M Herraiz, J Quiroga, I Herrero et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors J Clin Oncol 22 2004 1389 1397
78. L Heinzerling, G Burg, R Dummer, T Maier, PA Oberholzer, J Schultz et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy Hum Gene Ther 16 2005 35 48
79. BM Carreno, M Becker-Hapak, A Huang, M Chan, A Alyasiry, WR Lie et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity J Clin Invest 123 2013 3383 3394
80. SM Rudman, MB Jameson, MJ McKeage, P Savage, DI Jodrell, M Harries et al. A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma Clin Cancer Res 17 2011 1998 2005
81. ME Lutsiak, RT Semnani, R De Pascalis, SV Kashmiri, J Schlom, H Sabzevari Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 105 2005 2862 2868
82. + T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts Cancer Res 70 2010 6725 6734
83. HJ Pegram, JC Lee, EG Hayman, GH Imperato, TF Tedder, M Sadelain et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning Blood 119 2012 4133 4141
84. AM Gianni, S Siena, M Bregni, C Tarella, AC Stern, A Pileri et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation Lancet 2 1989 580 585
85. J Nemunaitis, JW Singer, CD Buckner, D Durnam, C Epstein, R Hill et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation Blood 76 1990 245 253
86. C Caux, C Dezutter-Dambuyant, D Schmitt, J Banchereau GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells Nature 360 1992 258 261
87. K Inaba, M Inaba, N Romani, H Aya, M Deguchi, S Ikehara et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor J Exp Med 176 1992 1693 1702
88. G Dranoff, E Jaffee, A Lazenby, P Golumbek, H Levitsky, K Brose et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci U S A 90 1993 3539 3543
89. X Cao, DW Ju, Q Tao, J Wang, T Wan, BM Wang et al. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice Gene Ther 5 1998 1130 1136
90. CL Tso, A Zisman, A Pantuck, R Calilliw, JM Hernandez, S Paik et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor Cancer Res 61 2001 7925 7933
91. JW Simons, B Mikhak, JF Chang, AM DeMarzo, MA Carducci, M Lim et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer Cancer Res 59 1999 5160 5168
92. R Soiffer, FS Hodi, F Haluska, K Jung, S Gillessen, S Singer et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma J Clin Oncol 21 2003 3343 3350
93. FS Hodi, MC Mihm, RJ Soiffer, FG Haluska, M Butler, MV Seiden et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci U S A 100 2003 4712 4717
94. PW Kantoff, CS Higano, ND Shore, ER Berger, EJ Small, DF Penson et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
95. AB Alexandroff, AM Jackson, MA O'Donnell, K James BCG immunotherapy of bladder cancer: 20 years on Lancet 353 1999 1689 1694
96. A Morales, D Eidinger, AW Bruce Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors J Urol 116 1976 180 183
97. DL Lamm, DE Thor, SC Harris, JA Reyna, VD Stogdill, HM Radwin Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer J Urol 124 1980 38 40
98. RJ Sylvester, AP van der Meijden, DL Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964 1970
99. RJ Sylvester, MA Brausi, WJ Kirkels, W Hoeltl, F Calais Da Silva, PH Powell et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder Eur Urol 57 2010 766 773
100. M Babjuk, W Oosterlinck, R Sylvester, E Kaasinen, A Böhle, J Palou-Redorta et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
101. SW Seow, JN Rahmat, BH Bay, YK Lee, R Mahendran Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette-Guérin or Lactobacillus rhamnosus strain GG in the healthy murine bladder Immunology 124 2008 419 427
102. S Prescott, K James, TB Hargreave, GD Chisholm, JF Smyth Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall J Urol 147 1992 1636 1642
103. H Suttmann, M Jacobsen, K Reiss, D Jocham, A Böhle, S Brandau Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation J Urol 172 2004 1490 1495
104. T Higuchi, M Shimizu, A Owaki, M Takahashi, E Shinya, T Nishimura et al. A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth Cancer Immunol Immunother 58 2009 1245 1255
105. TJ Kemp, AT Ludwig, JK Earel, JM Moore, RL Vanoosten, B Moses et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L Blood 106 2005 3474 3482
106. GG Jinesh, S Chunduru, AM Kamat Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL J Leukoc Biol 92 2012 233 244
107. R Breban, A Bisiaux, C Biot, C Rentsch, P Bousso, ML Albert Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response Oncoimmunology 1 2012 9 17
108. C Biot, CA Rentsch, JR Gsponer, FD Birkhäuser, H Jusforgues-Saklani, F Lemaître et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer Sci Transl Med 4 2012 137ra72
109. C Pieraerts, V Martin, P Jichlinski, D Nardelli-Haefliger, L Derre Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients Oncoimmunology 1 2012 694 698
110. J Elsäßer, MW Janssen, F Becker, H Suttmann, K Schmitt, U Sester et al. Antigen-specific CD4 T cells are induced after intravesical BCG-instillation therapy in patients with bladder cancer and show similar cytokine profiles as in active tuberculosis PLoS One 8 2013 e69892
111. SK Williams, DM Hoenig, R Ghavamian, M Soloway Intravesical therapy for bladder cancer Expert Opin Pharmacother 11 2010 947 958
112. MA O'Donnell Optimizing BCG therapy Urol Oncol 27 2009 325 328
113. MA O'Donnell, Y Luo, X Chen, A Szilvasi, SE Hunter, SK Clinton Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin J Immunol 163 1999 4246 4252
114. J Arnold, EC de Boer, MA O'Donnell, A Böhle, S Brandau Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma J Immunother 27 2004 116 123
115. Y Luo, J Henning, MA O'Donnell Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer Clin Dev Immunol 2011 2011 728930
116. S Brandau, H Suttmann Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement Biomed Pharmacother 61 2007 299 305
117. P Srivastava Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses Annu Rev Immunol 20 2002 395 425
118. S Basu, RJ Binder, T Ramalingam, PK Srivastava CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin Immunity 14 2001 303 313
119. + T cells Nat Immunol 6 2005 593 599
120. H Udono, PK Srivastava Heat shock protein 70-associated peptides elicit specific cancer immunity J Exp Med 178 1993 1391 1396
121. XY Wang, Y Li, MH Manjili, EA Repasky, DM Pardoll, JR Subjeck Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor Cancer Immunol Immunother 51 2002 311 319
122. X Chen, Q Tao, H Yu, L Zhang, X Cao Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity Immunol Lett 84 2002 81 87
123. J Gong, Y Zhang, J Durfee, D Weng, C Liu, S Koido et al. A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use J Immunol 184 2010 488 496
124. C Huang, H Yu, Q Wang, G Yang, W Ma, D Xia et al. A novel anticancer approach: SEA-anchored tumor cells expressing heat shock protein 70 onto the surface elicit strong anticancer efficacy Immunol Lett 101 2005 71 80
125. + CTL response by dendritic cell vaccine Cancer Res 65 2005 4947 4954
126. S Dai, T Wan, B Wang, X Zhou, F Xiu, T Chen et al. More efficient induction of HLA-A∗0201-restricted and carcinoembryonic antigen (CEA)-specific CTL response by immunization with exosomes prepared from heat-stressed CEA-positive tumor cells Clin Cancer Res 11 2005 7554 7563
127. W Chen, J Wang, C Shao, S Liu, Y Yu, Q Wang et al. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells Eur J Immunol 36 2006 1598 1607
128. F Belli, A Testori, L Rivoltini, M Maio, G Andreola, MR Sertoli et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings J Clin Oncol 20 2002 4169 4180
129. L Pilla, R Patuzzo, L Rivoltini, M Maio, E Pennacchioli, E Lamaj et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients Cancer Immunol Immunother 55 2006 958 968
130. A Testori, J Richards, E Whitman, GB Mann, J Lutzky, L Camacho et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group J Clin Oncol 26 2008 955 962
131. C Wood, P Srivastava, R Bukowski, L Lacombe, AI Gorelov, S Gorelov et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Lancet 372 2008 145 154
132. G Jego, A Hazoumé, R Seigneuric, C Garrido Targeting heat shock proteins in cancer Cancer Lett 332 2013 275 285
133. S Adams Toll-like receptor agonists in cancer therapy Immunotherapy 1 2009 949 964
134. PS Walker, T Scharton-Kersten, AM Krieg, L Love-Homan, ED Rowton, MC Udey et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms Proc Natl Acad Sci U S A 96 1999 6970 6975
135. H Xu, H An, Y Yu, M Zhang, R Qi, X Cao Ras participates in CpG oligodeoxynucleotide signaling through association with toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor 6 complex formation in macrophages J Biol Chem 278 2003 36334 36340
136. Y Shirota, H Shirota, DM Klinman Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells J Immunol 188 2012 1592 1599
137. I Miconnet, S Koenig, D Speiser, A Krieg, P Guillaume, JC Cerottini et al. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide J Immunol 168 2002 1212 1218
138. + T cells in protection Cancer Res 62 2002 7234 7240
139. AD Sandler, H Chihara, G Kobayashi, X Zhu, MA Miller, DL Scott et al. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma Cancer Res 63 2003 394 399
140. A Saha, M Bhattacharya-Chatterjee, KA Foon, E Celis, SK Chatterjee Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice Int J Cancer 124 2009 877 888
141. J Vollmer, AM Krieg Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists Adv Drug Deliv Rev 61 2009 195 204
142. MA Hofmann, C Kors, H Audring, P Walden, W Sterry, U Trefzer Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma J Immunother 31 2008 520 527
143. M Pashenkov, G Goëss, C Wagner, M Hörmann, T Jandl, A Moser et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma J Clin Oncol 24 2006 5716 5724
144. S Gnjatic, NB Sawhney, N Bhardwaj Toll-like receptor agonists: are they good adjuvants? Cancer J 16 2010 382 391
145. Q Liu, C Zhang, A Sun, Y Zheng, L Wang, X Cao Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I J Immunol 182 2009 6207 6216
146. + regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma Hepatology 59 2014 567 579
147. AM Krieg Toll-like receptor 9 (TLR9) agonists in the treatment of cancer Oncogene 27 2008 161 167
148. JW Friedberg, JL Kelly, D Neuberg, DR Peterson, JL Kutok, R Salloum et al. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma Br J Haematol 146 2009 282 291
149. E Erikçi, M Gursel, I Gürsel Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes Biomaterials 32 2011 1715 1723
150. H Conroy, NA Marshall, KH Mills TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours Oncogene 27 2008 168 180
151. M Kortylewski, M Kujawski, A Herrmann, C Yang, L Wang, Y Liu et al. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy Cancer Res 69 2009 2497 2505
152. KE de Visser, A Eichten, LM Coussens Paradoxical roles of the immune system during cancer development Nat Rev Cancer 6 2006 24 37
153. RA Flavell, S Sanjabi, SH Wrzesinski, P Licona-Limón The polarization of immune cells in the tumour environment by TGFbeta Nat Rev Immunol 10 2010 554 567
154. FS Hodi, M Butler, DA Oble, MV Seiden, FG Haluska, A Kruse et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients Proc Natl Acad Sci U S A 105 2008 3005 3010
155. JA Klapper, SG Downey, FO Smith, JC Yang, MS Hughes, US Kammula et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006 Cancer 113 2008 293 301
156. ZZ Yang, DM Grote, SC Ziesmer, T Niki, M Hirashima, AJ Novak et al. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma J Clin Invest 122 2012 1271 1282